A Narrative Review on Current Development and Future Prospects for the Treatment of Dengue Virus Infection
| Autor: | Sheikh Abdul Khaliq, Muneer Khan, Saquib Azeem, Anab Fatima |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Liaquat National Journal of Primary Care, Vol 6, Iss 2, Pp 165-173 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2707-3521 2708-9134 |
| DOI: | 10.37184/lnjpc.2707-3521.6.26 |
| Popis: | Incidences of dengue-virus infection are increasing globally. Around 3.90 billion population is at high risk of infection. There is no cure/ prevention available. Hence aim of the current review was the evaluation of current development and prospects for the production of safe anti-dengue drugs. The data of review was synthesized by PRISMA. Grading of Recommendation Assessment, Development, and Evaluation criteria were employed to establish the quality of the literature. Many drugs/compounds have shown promising prospects. Target site of these drugs on dengue virus were inhibition of replication (N-sulfonyl peptide-hybrids, milk-exosomes, sunitinib, schisandrin-A, cavinafungin, minocycline, 4-hydroxyphenyl retinamide, Goniothalamus umbrosus, Dryopteris crassirhizoma, Morus alba, statins), protease-enzyme (Thiazolidinone-peptide, nelfinavir, carnosine, 1,2-benzisothiazol-3(2H)- one and 1,3,4-oxadiazole), capsid-protein (Juglanin and silymarin), NS4B-gene (Desatinib), entry-in-host-cell (Duramycin, glycodendrimers, curdlan sulfate), RNA-capping (Lanatoside-C), fusion (Chloroquine) and NS3-helicase (Suramina). Many compounds/drugs are found effective by targeting the structural proteins of the dengue virus to use as a therapy in the future. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|